Industry Relations Council (IRC)
The ITNS Industry Relations Council is available to organizations that support the goals and mission of ITNS and provide products or services used in the area of transplantation. Membership is for one year. It is a nonvoting membership with benefits extended to a single corporate-designated representative. Membership is available at an associate or executive level. Read about the benefits of joining the IRC and apply today.
3260 Bayshore Blvd
Brisbane, CA 94005
CareDx, Inc. is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
To learn about the first and only transplant dd-cfDNA developed specifically for transplant recipients, visit: https://www.caredx.com/allosure
Read about the established standard for heart transplant surveillance here: https://www.caredx.com/heart-transplant/
Want to learn how to keep your transplant patients safe at home while up-to-date with their regular transplant labs? Visit: https://www.caredx.com/remotrac
Atara Biotherapeutics, Inc.
611 Gateway Blvd, Suite 900
South San Fracisco, CA 94080
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s lead candidate is a T-cell immunotherapy being investigated for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+PTLD).
View clinical trial information
1001 Winstead Drive, 3rd floor, Suite 310
Cary, North Carolina 27513
Veloxis Pharmaceuticals (Veloxis) is a specialty pharmaceutical company focused on the development and commercialization of a novel product for the prevention of organ rejection in kidney transplant patients. All clinical studies including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale. Veloxis is commited to ensuring access to ENVARSUS XR regardless of a patient's insurance or financial situation. Patient Financial Support Resources
Natera is a global leader in cell-free DNA (cfDNA) testing. Our mission is to change the management of disease worldwide in women's health, oncology and organ health. Developed by our legacy in cfDNA, the Prospera test is optimized to be a precise, reliable tool for early, clinically meaningful rejection assessment.
201 Industrial Rd, Ste 410
San Carlos, CA 94070